Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stroke 1Sarcoma 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Microsatellite Instability 1Metastatic Bladder Urothelial Carcinoma 1Lymphoma 1Kidney Failure, Chronic 1Extensive Stage Small Cell Lung Carcinoma 1Diabetes Mellitus 1Coronary Artery Disease 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1

Interventions

durvalumab 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Microsatellite Instability × Immunoglobulin G × Clear all
NCT02966587 2018-01-17

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of Washington

Phase 2 Withdrawn

Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡